RxDoctor Payments Data

Makayla Ciavardone

Nurse Practitioner · Avon Park, FLNPI 1841974284

Payments from drug & device makers

$2,810in general payments, 2019–2025

Across 140 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$475
  • Amgen$391
  • UCB, Inc.$378
  • AstraZeneca$342
  • Pfizer$332
  • Johnson & Johnson$266
  • plus $625 from 9 others

What the payments were for

  • Food & beverage$2,71196%
  • Education$994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,810 in reported general payments places this provider in the 85th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$575,305
Medicare patients
393
Services billed
52,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab66$528,010
Enbrel SureclickEtanercept38$327,584
RinvoqUpadacitinib40$285,514
Xeljanz XrTofacitinib Citrate31$206,021
ProliaDenosumab58$102,358
TymlosAbaloparatide25$69,764
OtezlaApremilast13$64,558
Hydroxychloroquine Sulfate230$9,806
SavellaMilnacipran Hcl11$9,054
Leflunomide113$6,073
MethotrexateMethotrexate Sodium285$5,241
Tramadol Hcl340$2,152
Gabapentin130$1,951
Celecoxib96$1,932
Pregabalin90$1,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Savella$475$294,56851 claims
AmgenProlia, Otezla$391$166,91671 claims
Radius Health, Inc.Tymlos$80$69,76425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Avon Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →